Back to Newsroom

Arrowhead Pharmaceuticals to Present at Upcoming Conferences

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) will make presentations at the following upcoming events:

The 25th Annual Credit Suisse Healthcare Conference – Scottsdale, AZ, November 6-8, 2016

November 7, 11:30 a.m. MST – Christopher Anzalone, Ph.D., Arrowhead president and CEO will deliver a corporate presentation

The Liver Meeting® 2016, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) – Boston, November 11-15, 2016

November 13, 5:30 p.m. EST – Christine Wooddell, Ph.D., Arrowhead director of liver targeting will deliver an oral presentation titled, “RNA interference therapeutic ARC-AAT prevents production of Z-alpha1 antitrypsin polymers and reverses liver disease phenotype in PiZ mouse model

November 13, 8:00 a.m. EST – Alice Turner, MBChB (Hons), MRCP, PGCE (MedEd), PhD, University of Birmingham, Edgbaston Birmingham, United Kingdom, and coauthors, will deliver a late-breaking poster presentation titled, “RNA interference (RNAi) with ARC-AAT provides deep and prolonged knockdown of alpha-1 antitrypsin levels in healthy volunteers

American Heart Association’s Scientific Sessions 2016 – New Orleans, November 12-16, 2016

November 14, 10:40 a.m. CST – Stacey Melquist, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, “Targeting factor XII (F12) with a novel RNAi delivery platform as a prophylactic treatment for thromboembolism

November 14, 2:00 p.m. CST – Stacey Melquist, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, “Targeting apolipoprotein(a) with a novel RNAi delivery platform as a prophylactic treatment to reduce risk of cardiovascular events in individuals with elevated lipoprotein (a)

The 28th Annual Piper Jaffray Healthcare Conference – New York, November 29-30, 2016

November 30, 8:30 a.m. EST – Christopher Anzalone, Ph.D., Arrowhead president and CEO will deliver a corporate overview in a fireside chat with Ted Tenthoff, senior research analyst, Piper Jaffray

Click here to read the full release